Dysregulated apoptosis and NFkB expression in COPD subjects by Brown, Vanessa et al.
BioMed CentralRespiratory Research
ssOpen AcceResearch
Dysregulated apoptosis and NFκB expression in COPD subjects
Vanessa Brown*1, J Stuart Elborn1, Judy Bradley2 and Madeleine Ennis1
Address: 1Respiratory Research Group, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's 
University Belfast, Belfast, UK and 2Institute of Rehabilitation Studies, University of Ulster, Coleraine, UK
Email: Vanessa Brown* - v.brown@qub.ac.uk; J Stuart Elborn - stuart.elborn@belfasttrust.hscni.net; Judy Bradley - jm.bradley@ulster.ac.uk; 
Madeleine Ennis - m.ennis@qub.ac.uk
* Corresponding author    
Abstract
Background: The abnormal regulation of neutrophil apoptosis may contribute to the ineffective
resolution of inflammation in chronic lung diseases. Multiple signalling pathways are implicated in
regulating granulocyte apoptosis, in particular, NFκB (nuclear factor-kappa B) signalling which
delays constitutive neutrophil apoptosis. Although some studies have suggested a dysregulation in
the apoptosis of airway cells in chronic obstructive pulmonary disease (COPD), no studies to date
have directly investigated if NFκB is associated with apoptosis of airway neutrophils from COPD
patients. The objectives of this study were to examine spontaneous neutrophil apoptosis in stable
COPD subjects (n = 13), healthy smoking controls (n = 9) and non-smoking controls (n = 9) and
to investigate whether the neutrophil apoptotic process in inflammatory conditions is associated
with NFκB activation.
Methods: Analysis of apoptosis in induced sputum was carried out by 3 methods; light microscopy,
Annexin V/Propidium iodide and the terminal transferase-mediated dUTP nick end-labeling
(TUNEL) method. Activation of NFκB was assessed using a flow cytometric method and the
phosphorylation state of IκBα was carried out using the Bio-Rad Bio-Plex phosphoprotein IκBα
assay.
Results: Flow cytometric analysis showed a significant reduction in the percentage of sputum
neutrophils undergoing spontaneous apoptosis in healthy smokers and subjects with COPD
compared to non-smokers (p < 0.001). Similar findings were demonstrated using the Tunel assay
and in the morphological identification of apoptotic neutrophils. A significant increase was observed
in the expression of both the p50 (p = 0.006) and p65 (p = 0.006) subunits of NFκB in neutrophils
from COPD subjects compared to non-smokers.
Conclusion: These results demonstrate that apoptosis is reduced in the sputum of COPD
subjects and in healthy control smokers and may be regulated by an associated activation of NFκB.
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by an inflammatory infiltrate consisting mainly of
neutrophils [1], with increased neutrophils and inflam-
matory mediators in both bronchial tissue and airways of
COPD patients [2-4]. In several acute and chronic neu-
trophilic diseases, such as cystic fibrosis and acute respira-
tory distress syndrome (ARDS) there is a delay in
neutrophil apoptosis resulting in persistent inflammation
[5,6]. Studies investigating neutrophil apoptosis in COPD
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shown a reduction in spontaneous apoptosis during an
exacerbation of COPD that increases with treatment [7] or
no changes in the rate of apoptosis of cultured blood neu-
trophils between stable COPD subjects, healthy smokers
and healthy control non-smokers [8]. The only study to
date investigating spontaneous neutrophil apoptosis in
sputum from COPD subjects was unable to identify any
differences in apoptosis from moderate to severe disease
compared to controls [9]. However this study only used
one method to directly assess spontaneous neutrophil
apoptosis, and since the identification of cells that have
clearly adopted an apoptotic phenotype often requires
more than one method for determining apoptosis, it has
been recommended to use at least two methods to meas-
ure apoptosis in order to confirm data [10]. Other studies
investigating apoptosis-related factors in COPD have
shown that plasma levels of soluble Fas, an inhibitor of
apoptosis, are only increased in patients with severe
COPD, while plasma levels of the inducer of apoptosis,
sFasL, appear unchanged with disease severity [11,12].
Since the transcription factor NFκB controls the expres-
sion of many inflammatory and apoptotic genes [13-15],
it is of particular interest in a disease such as COPD where
neutrophil inflammation persists. The activated form of
NFκB is a heterodimer, usually made up of 2 Rel family
proteins, p65 (RelA) and p50 (NFκB) subunits. In unstim-
ulated cells NFκB is sequestered in the cytoplasm due to
its binding to IκBα and IκBβ. Following cell stimulation,
IκB is rapidly phosphorylated by specific protein kinases
leading to proteolytic degradation and allowing NFκB to
translocate to the cell nucleus where it binds to specific κB
recognition elements in the promoter region of target
genes (reviewed in [16]). Studies investigating NFκB
expression in COPD subjects provide evidence for an
increase in NFκB translocation in lung tissue and sputum
from COPD subjects compared to non-smoking controls,
which appears to be associated with an exacerbation [17-
19]. A recent study, described how a number of transcrip-
tion factors, including NFκB, are overexpressed in bron-
chial epithelium from smokers with COPD [20].
In order to elucidate the degree of constitutive neutrophil
apoptosis in the inflammatory airways of COPD subjects
and the potential involvement of NFκB in this process we
used three methods to investigate neutrophil apoptosis in
COPD and determine any associated increase in NFκB
activation in airway neutrophils. We hypothesised that
there is a delay in neutrophil apoptosis in COPD subjects
that is mediated, in part, by NFκB binding in neutrophils.
Methods
Patients
Age-matched stable COPD patients (n = 13), healthy con-
trol smokers (n = 9) and control non-smokers (n = 9) were
included in the study (all subjects were over 50 years).
COPD subjects had a history consistent with COPD as
described in the British Thoracic Society guidelines [21].
Inclusion criteria for stable COPD subjects were as fol-
lows: no exacerbation within the preceding 4 weeks, over
50 years; ≥ 20 packyear history of smoking; FEV1<70%
predicted, FEV1/FVC ratio < 70% and <15% reversibility
in response to β2 agonists. They were receiving treatment
with anticholinergic, β2-agonists and/or steroids. Exclu-
sion criteria were: long-term oral corticosteroids; lung
neoplasm and other serious concomitant disease.
Control healthy smokers (HS) were over 50 years and ≥ 20
packyear history of smoking; control non-smokers (NS).
Both control groups had normal lung function and sub-
jects were excluded if there was evidence of atopy/asthma,
chest disease, recent respiratory tract infection or antibi-
otic/steroid treatment. The Queen's University Belfast
Research Ethics Committee approved the study. Written
informed consent was obtained from all participants.
Sputum induction/processing
Sputum induction was performed using the Sonix 2000
nebuliser (Clement Clarke International Ltd, Harlow, UK)
using a method described previously [22,23]. Briefly, 3%
saline was nebulised for 20 minutes. Forced expiratory
volume in 1 second (FEV1) and forced vital capacity (FVC)
(Vitalograph) were determined by spirometry according
to ATS standards. Nebulisation was stopped if FEV1 fell by
>20% at any stage. Sputum samples were processed
within 2 hours adapting methods described by Pavord et
al. [22]. The supernatant was removed from the cell pellet
and stored at -70°C for future analysis. Cytospin slides
were made and stained with Diff Quik (Clin-Tech Ltd,
Essex, UK).
Inflammatory mediators
Sputum CRP concentrations were measured with an
ELISA according to the manufacturer's instructions
(Bender MedSystems, Austria). Sputum concentrations of
IL-6, IL-8 and GM-CSF were determined using a Bioplex
multiplex assay kit (Bio-Rad, Hercules, CA) and the
Cytokine Reagent kit (Bio-Rad) according to the manufac-
turer's protocol.
Measurement of apoptosis
Apoptotic neutrophils were identified by characteristic
morphological changes (condensation of nuclear mate-
rial, 'rounding' of nucleus, shrinkage and pallor of cyto-
plasm and shrinkage of the cell) [24,25] and expressed as
a percentage of total neutrophils counted.
Apoptosis was analysed flow cytometrically using 2 tech-
niques: (1) Samples were labelled with Annexin V (Av)
and propidium iodide (PI), following manufacturer's
staining protocol, to quantify the percentage of cells
undergoing apoptosis and/or necrosis (Pharmingen, SanPage 2 of 12
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Epics Elite and Epics XL flow cytometer (Beckman Coul-
ter, UK Ltd). Samples were gated on the granulocyte pop-
ulation using a forward scatter and side scatter plot with a
minimum of 5,000 gated events samples gated. Controls
included to set-up compensation and quadrants were:
cells stained with Annexin-V FITC alone and cells stained
with PI alone. To eliminate cellular debris from the anal-
ysis the discrimination level was set at 100. Cells were
defined as apoptotic (AV+/PI-), secondary necrotic (AV+/
PI+), necrotic (AV+/PI-), or neither apoptotic nor necrotic
(AV-/PI-). Each subpopulation was expressed as a percent-
age of the total population of granulocytes, (2) The In situ
cell death detection kit (Roche Diagnostics GmbH, Ger-
many) was used according to the manufacturer's instruc-
tions to determine the extent of DNA fragmentation and
the proportion of apoptosis. Analysis was performed
using a Coulter Epics Elite and Epics XL flow cytometer
(Beckman Coulter, UK Ltd). Samples were gated on the
granulocyte population as described above. Negative con-
trol consisted of cells without incubation with terminal
transferase, and DNase I was used as a positive control.
Apoptotic cells (i.e. those cells with DNA strand breaks)
were identified as fluorescein-dUTP positive (FL1: fluores-
cent-1).
Plasma concentrations of sFas-L, an inducer of apoptosis,
and sFas, an inhibitor of apoptosis, were measured using
commercially available ELISA assays (IDS Ltd. UK).
Quantification of NF B activation and I B  
phosphorylation
The percentage of granuloctyes positive for the p50/p65
subunits of NFκB in induced sputum was determined
using an adapted published flow cytometric method [26].
Nuclei were isolated using the CycleTest PLUS DNA Rea-
gent Kit (BD Biosciences) according to the manufacturer's
instruction and stained with anti-human NFκB (p50 or
p65) antibody (Santa Cruz Biological, Germany) or iso-
type-matched control (Southern Biotech, USA), followed
by anti-rabbit FITC conjugate (Sigma-Aldrich, Inc. USA)
and then propidium iodide (PI) solution. Localisation of
granulocyte sputum nuclei in the FS/SC dot plot was
determined using previously separated granulocyte
nuclei. Acquisition of stained nuclei (minimum 5000
events) was carried out on an Epics Elite and Epics XL flow
cytometer. Single nuclei were gated on the basis of PI
staining (FL-3 measured at 630 nm), after doublet elimi-
nation by FL-3 peak versus integral. Positive p50 or p65
expression (determined in the FL-1 plot) was expressed as
percentage of granulocyte nuclei.
Protein lysates were prepared by using Cell lysis kit (Bio-
Rad, USA) and the presence of phosphorylated IκBα was
detected by Bio-Plex Phospho-IκBα (Ser32/Ser36) assay
kit (Bio-Rad, USA) according to the manufacturer's proto-
col. Data were collected and analysed using the Bio-Plex
suspension array system (Bio-Rad Laboratories USA).
Statistical analysis
Statistical analysis was performed using SPSS version 13.0
(SPSS inc., Chicago, IL, USA). Comparisons between
groups were performed with the one-way ANOVA fol-
lowed by Tukey's post-hoc test or the nonparametric
Kruskal-Wallis test followed by Dunn's post-hoc test
when the data were not normally distributed. Direct com-
parisons between two groups were performed with the
nonparametric Mann-Whitney test. A p value of less than
0.05 was regarded as significant.
Results
Demographics are summarised in Table 1. Sputum induc-
tion was not successful in all subjects; a total of 14 COPD,
13 healthy smokers and 12 non-smoking controls were
initially recruited for the study, with 13, 9 and 9 subjects
respectively producing an adequate sample to proceed
with experiments. Furthermore some subjects did not pro-
duce enough for all analyses to be carried out and hence
numbers between groups may vary.
Analysis of the differential and total cell counts showed
significant differences in the percentage of macrophages,
neutrophils and epithelial cells (expressed as a percentage
of total cell count) between all 3 groups (Table 2). The
percentage of neutrophils was higher in COPD patients
compared with healthy smokers and non-smokers (p <
0.05). Conversely the percentage of macrophages was
decreased in COPD patients (p < 0.05) compared to
healthy smokers and non-smokers.
Inflammatory mediators: C-reactive protein (CRP) and 
cytokines
To investigate airway inflammation the levels of the acute-
phase reactant C-reactive protein, CRP, IL-6, IL-8 and GM-
CSF were measured (Figure 1). In sputum there was a
median 30-fold increase in CRP in COPD subjects com-
pared to both healthy smokers and non-smokers and con-
centrations of IL-6 and IL-8 in sputum were significantly
higher in COPD subjects compared to non-smokers. GM-
CSF levels were higher, but not statistically different, in
COPD subjects compared to healthy smokers and non-
smokers.
Quantification of neutrophil apoptosis
The results from the three different methods used to assess
apoptosis are summarised in Table 3. Using one-way
ANOVA test, the percentage of apoptotic cells were signif-
icantly different between all 3 assays (p < 0.0001) with
post-hoc test showing a higher percentage of Tunel posi-
tive cells, Av+/PI+ and Av-/PI+ cells compared to the per-Page 3 of 12
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apoptosis (Figure 2) (p < 0.001, p < 0.001 and p < 0.05
respectively). Also there was a higher percentage of apop-
totic neutrophils detected by the Tunel assay compared
with those cells that were Av+/PI- (p < 0.0.5). There was a
significant correlation between Av+/PI- neutrophils (early
apoptotic neutrophils) and the percentage of neutrophils
displaying morphological features of apoptosis (r = 0.67,
p < 0.001, Pearson correlation).
Using the Annexin V/PI method for the assessment of
apoptosis, granulocytes were gated using the forward and
side scatter dot plot (Figure 3a) and assessed for staining
of Annexin V and/or PI (Figure 3b). Subjects with COPD
and healthy smokers had a statistically significant reduc-
tion in early stage apoptosis (as measured by Av+/PI-
staining) compared to non-smokers, p < 0.001 (Figure
3c). There was a trend for an increase in late apoptosis/sec-
ondary necrosis (Av+/PI+) in subjects with COPD and
healthy smokers compared to non-smokers (Figure 3c).
Despite differences in methodologies, similar findings to
those with the Annexin V/PI assay were seen using both
the Tunel assay and the morphological identification of
apoptosis (Figure 4). A significant reduction in the per-
centage of Tunel positive cells was observed in COPD sub-
jects compared to non-smokers and also in the percentage
of cells that were morphologically identified as apoptotic
using light microscopy (Figure 4).
This study also examined the plasma levels of soluble Fas/
APO-I receptor (sFas), an inhibitor of apoptosis, and sol-
uble Fas ligand (sFas-L), an inducer of apoptosis, in all
three subject groups (Figure 5). Although plasma sFas lev-
els were slightly higher in COPD subjects compared to
non-smokers there was no statistical significance between
the groups. Similarly assessment of sFasL showed no sig-
nificant differences between the subject groups.
I B  phosphorylation and NF B activation in induced 
sputum
Localisation of single granulocyte nuclei allowed for the
quantification of NFκB activation in sputum from COPD
subjects, healthy smoking controls and non-smoking con-
trols (Figure 6a and 6b). p50 and p65 subunit expression
in sputum neutrophil nuclei showed a significant increase
in the expression of both NFκB subunits in COPD sub-
jects (p50, p = 0.006 and p65: p = 0.006) compared to
non-smokers (Figure 6c). Although there was a higher
expression of p50 and p65-positive neutrophil nuclei in
healthy smokers compared to non-smokers, this did not
Table 1: Demographic and lung function data
COPD
n = 13
Healthy smokers (HS)
n = 9
Non-smokers(NS)
n = 9
Age 68.38 (1.86) 61.56 (3.13) 68.67(1.90)
Sex (M/F) 7/6 6/3 1/8
Smoker (current/ex) 5/7 9/0 0/2
Pack Years 49.08 (10.01) 42.28 (5.68)
FEV1(L) 0.88 (0.12) 2.55 (0.16) 1.97 (0.12)
FEV1% 36.25 (3.94) 90.22(4.13) 93.75 (9.22)
FVC (L) 1.77 (0.1) 3.56 (0.18) 2.43 (0.12)
FVC % 59.67 (3.88) 101.2 (5.92) 92.0 (8.27)
Ratio (FEV/FVC) 48.98 (5.21) 71.66 (2.90) 81.23 (3.70)
Data are expressed as mean (SEM).
FEV1: Forced expiratory volume in the first second.
FVC: Forced vital capacity
Table 2: Total and differential sputum cell counts
COPD Healthy smokers (HS) Non-smokers (NS) *p value
Total cell count (× 106/g sputum) 2.43 (0.7) 3.26 (1.93) 1.32 (0.46) NS
% Macrophage 32.40 (4.30) 47.90 (3.24) 44.28 (3.80) < 0.05
% Neutrophil 58.78 (4.90) 44.66 (3.02) 41.35 (4.32) < 0.05
% Eosinophils 3.27 (1.79) 0.83 (0.16) 1.92 (0.84) NS
% Lymphocytes 3.54 (0.86) 3.17 (0.64) 8.0 (3.31) NS
% Epithelial cells 0.76 (0.30) 1.80 (0.32) 0.72 (0.28) < 0.05
% Squamous cells 1.27 (0.53) 1.66 (0.54) 2.04 (0.81) NS
Data are expressed as mean (SEM).
* Comparison between the 3 groups using one-way ANOVA.
NS: not significantPage 4 of 12
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sFasL in plasma from non-smokers and activation of p65
in sputum (r = -0.90, p = 0.002, Spearman's correlation).
To further assess the role of NFκB in controlling sputum
neutrophil apoptosis in COPD subjects, the phosphoryla-
tion of IκBα in sputum was investigated. Although there
was a trend towards a higher level of phosphorylated IκBα
in healthy smokers compared to non-smokers, this did
not reach significance (Figure 7).
Discussion
In this study, flow cytometric analysis demonstrated that
apoptosis is abnormally regulated in COPD subjects that
this appears to be, at least in part, regulated by the activa-
tion of NFκB. It is postulated that oxidative stress and sur-
vival factors contribute to the longevity of the neutrophil
that perhaps overwhelms the macrophage clearance
mechanism leading to persistent airway inflammation in
COPD subjects.
(a) CRP levels in sputum from non-smokers, n = 7 (NS), healthy smokers, n = 9 (HS) and in COPD subjects, n = 12Figure 1
(a) CRP levels in sputum from non-smokers, n = 7 (NS), healthy smokers, n = 9 (HS) and in COPD subjects, n 
= 12. (b) Log10 IL-6 levels (pg/ml) in sputum from non-smokers, n = 5 (NS), healthy smokers, n = 5 (HS) and in COPD sub-
jects, n = 12 (c) IL-8 levels (pg/ml) in sputum from non-smokers, n = 5 (NS), healthy smokers, n = 5 (HS) and in COPD sub-
jects, n = 12 (d) Log10 GM-CSF levels (pg/ml) in sputum from non-smokers, n = 5 (NS), healthy smokers, n = 5 (HS) and in 
COPD subjects, n = 12. Data are expressed as mean (SEM). p values shown is from Tukey's multiple comparison post-hoc anal-
ysis following one-way ANOVA.Page 5 of 12
(page number not for citation purposes)
Respiratory Research 2009, 10:24 http://respiratory-research.com/content/10/1/24Assays investigating apoptosis should be interpreted with
care. Firstly, cells can display morphological features of
apoptosis without DNA fragmentation [27,28] and it is
also possible that the Tunel assay can generate false-posi-
tive results since random DNA fragmentation during
necrosis may also generate 3'OH DNA ends [29]. Despite
the concept that the morphological detection and quanti-
fication of apoptotic cells is regarded as the 'gold standard'
method [30], results from this study support the notion
that in some instances morphological identification of
apoptotic cells may underestimate apoptosis [31]. There-
fore it is imperative that at least 2 different methods are
used in the quantification of apoptosis, to confirm data
and to ensure different stages of apoptosis are investi-
gated. Despite differences in methods, all three assays
showed significant reduction in the percentage of apop-
totic neutrophils between COPD subjects and non-smok-
ers. Quantification of apoptosis by Annexin V/PI staining
also showed a decrease in healthy smoking subjects com-
pared to non-smokers. This study, along with others has
reported an increase in airway neutrophils in COPD sub-
jects [2-4,32] and it is plausible that this accumulation of
neutrophils may be due to both increased recruitment in
the airways and inhibition of apoptosis [33,34].
Our findings show that the percentage of neutrophils in
early stage apoptosis are significantly reduced in COPD
subjects and in healthy smokers and concomitantly have
a higher percentage of neutrophils undergoing secondary
necrosis compared to non-smokers. Similar results were
shown using by both the Tunel method and by light
microscopic morphological identification. Several factors
can influence the process of neutrophil apoptosis. While
data suggests that corticosteroids inhibit neutrophil apop-
tosis [35], others have shown that corticosteroids do not
affect spontaneous neutrophil apoptosis in COPD
patients [7]. More recently work suggests that β 2 agonists
alone have negligible effects on neutrophils but together
with corticosteroids actually enhances inhibition of apop-
tosis [36]. One limitation of this study is the lack of inves-
tigation of the influence of medication on neutrophil
apoptosis. Although COPD treatment included β2 ago-
nists, corticosteroids and/or anti-cholinergics, all healthy
smokers recruited in this study had not received any
recent oral/inhaled steroids and therefore it is likely that
the similar inflammatory status observed in COPD and
healthy smokers is not a consequence of corticosteroid
treatment. Furthermore it has been suggested that in vitro
findings showing delayed neutrophil apoptosis due to
corticosteroids is more than likely overwhelmed by the in
vivo inhibition of the anti-apoptotic effects of inflamma-
tory cytokines [7]. IL-6, IL-8 and GM-CSF are important
cytokines in the regulation of airway inflammation and
several studies have shown these cytokines play a key role
in the pathophysiology of COPD [37]. In vitro studies
have shown that the pro-inflammatory cytokines GM-
CSF, IL-8 and IL-6 inhibit apoptosis of granulocytes [38-
41] and therefore the observed increase in IL-6 and IL-8 in
COPD subjects compared to non-smokers may account
for the reduced neutrophil apoptosis in COPD subjects.
Apoptotic sputum neutrophils identified using light micros-copyFigure 2
Apoptotic sputum neutrophils identified using light 
microscopy. Typical apoptotic neutrophils displaying loss of 
chromatin filaments (heavy arrow) and shrinkage of the 
nucleus (thin arrow).
Table 3: Comparison of apoptotic assays from sputum neutrophils
Method 1 Method 2 Method 3
% Apoptotic neutrophils1 % Av+/PI- % Av+/PI+ % Av-/PI+ % Tunel
+ve cells2
ALL SUBJECTS 10.9
(1.22)
17.19
(2.85)
37.63
(5.27)
21.67
(4.02)
28.56
(4.09)
Method 1: Microscopic morphological identification. Method 2: Annexin V/Propidium iodide (PI) staining. Method 3: Identification of DNA 
fragmentation (Tunel assay).
% AV+/PI-: early apoptosis, % AV+/PI+: later stage apoptosis/secondary necrosis and % AV-/PI+: necrosis.
1Significantly different compared to Tunel +ve cells (p < 0.001), % AV+/PI+ (p < 0.001) and % AV-/PI+ neutrophils using Tukey's multiple comparison 
post-hoc test. 2Significantly different compared to % AV+/PI- cells (p < 0.05).
Data are expressed as mean (SEM)Page 6 of 12
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the low number of cells and indeed for some patients pro-
duction of an adequate volume of sputum is virtually
impossible. To this end we were limited to measuring Fas
and FasL expression in the plasma of all subjects. Fas has
been shown to be an important mediator of apoptotic cell
death, as well as being involved in inflammation. Results
in this study suggest a trend for an increase in sFas, an
inhibitor of apoptosis, in plasma from COPD subjects.
The strong inverse relationship between sFasL (inducer of
apoptosis) in plasma from non-smokers and activation of
p65 in sputum observed in this study lends support to the
concept that an increase in nuclear IκBα is associated with
inhibition of NFκB activation and the subsequent induc-
tion of apoptosis [42]. In bronchial epithelium, there is an
increase in p65 expression (regarded as NFκB activation)
in COPD patients and smokers with normal lung func-
tion, compared to normal control subjects [43] and inves-
Annexin V/PI analysis in induced sputum.Figure 3
Annexin V/PI analysis in induced sputum. (a) Horizontal axis represents side scatter (SS) and vertical axis represents for-
ward scatter (FS) (linear scale). Gated area, containing granulocytes, represented by area marked M (b) Horizontal axis repre-
sents intensity of staining for Av (Annexin V) (logarithmic scale) and vertical axis intensity of staining for PI (logarithmic scale). 
Typical dot plot representing populations of early apoptotic (AV+/PI-), secondary necrotic (AV+/PI+), and necrotic granulocytes 
(AV+/PI-) (c) Analysis of neutrophil apoptosis in sputum using the Annexin V/Propidium iodide assay. One way ANOVA 
showed a reduction in Av+/PI- in healthy smokers (HS) and COPD subjects compared to non-smokers (NS), p < 0.001. % AV+/
PI-: early apoptosis, % AV+/PI+: later stage apoptosis/secondary necrosis:% AV-/PI+: necrosis.
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increase in NFκB translocation, possibly in macrophages,
during an exacerbation in COPD subjects [17,18]. How-
ever, the study by Drost et al. analysed sputum leukocytes
as a whole and therefore does not indicate which cells
may be associated with NFκB translocation. It seems that
there are differences in the NFκB regulation of apoptosis
between neutrophils and other cells, with the inhibition
of NFκB inducing apoptosis in murine B cells [44], and in
other cell types, activation of NFκB seems to correlate with
Percent of apoptotic neutrophils in sputum by DNA strand breaks (Tunel) and morphological features of apoptosisFigure 4
Percent of apoptotic neutrophils in sputum by DNA strand breaks (Tunel) and morphological features of 
apoptosis. Data are displayed as median (interquartile range). Kruskal-Wallis test was used to determine any significant differ-
ences between the 3 groups, followed by post-hoc analysis (Dunn's Multiple Comparison test). p values shown are from post-
hoc analysis.
sFas and sFasL levels in plasma from non-smokers (NS), healthy smokers (HS) and COPD subjectsFigure 5
sFas and sFasL levels in plasma from non-smokers (NS), healthy smokers (HS) and COPD subjects. Data are dis-
played as median (interquartile range).Page 8 of 12
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centage of neutrophil NFκB phosphorylation in COPD
subjects compared to non-smokers in this study provides
evidence to support a role for NFκB translocation and acti-
vation in delaying apoptosis in COPD subjects and to date
is the only reported study to investigate the activation of
this transcription factor and its' inhibitor, IκBα, in neu-
trophils from induced sputum. A higher expression of p50
and p65-positive neutrophil nuclei was observed in
healthy smokers compared to non-smoking controls,
however, this did not reach significance, possibly due to
the low number of non-smoking controls available and
the inter-subject variability. To fully understand the
involvement of NFκB in neutrophil apoptosis in COPD, it
is important to assess IκB phosphorylation state as this
precedes ubiquitination and degradation and subsequent
NFκB activation. However, the quantity of cellular lysates
varied greatly from patient to patient and restricted analy-
sis of the phosphorylation state of IκBα in all subjects.
Therefore a lack of power meant there was no observed
statistical difference in IκBα phosphorylation between the
three groups.
NF[kappa]B analysis in induced sputum.Figure 6
NF[kappa]B analysis in induced sputum. (a) Identification of granulocyte nuclei (gated area shown) in sputum by compar-
ing separated granulocyte nuclei from sputum sample (left) with whole sputum nuclei (right) (b) Sputum granulocyte nuclei: FL-
3-peak versus FL-3 integral dot plot showing a singlet gate to exclude aggregates (c) Percentage of neutrophils expressing p50 
and p65 (NFκB activation) in induced sputum in non-smokers (NS), healthy smokers (HS) and in COPD subjects. In COPD 
subjects closed symbols = current smokers and open symbols = ex-smokers. Mann-Whitney U test was used to determine any 
significant differences. COPD n = 12; HS n = 6; NS n = 8. Line represents median value.
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may be due to the presence of high levels of cytokines
which prolong the lifespan of the neutrophil (eg. GM-
CSF), the ability of IL-8 and IL-6 (both of which were sig-
nificantly increased in COPD subjects) to suppress spon-
taneous apoptosis [46,47] or possibly due to viral and/or
bacterial infection. An ongoing bacterial infection may
exacerbate airway inflammation in COPD subjects by sig-
nalling via Toll-like receptor (TLR) activation to activate
NFκB and induce expression of NFκB-regulated genes
thereby inhibiting neutrophil apoptosis. It is well known
that cigarette smoke is the most important risk factor for
COPD, however the exact reasons as to why only a minor-
ity of smokers (15–20%) develop clinical COPD remain
unknown. This study, although suggesting that the
inflammatory status and activation state of neutrophils
between COPD subjects and healthy smokers are similar,
does not address the issue of increased susceptibility to
smoking in COPD development. Previous cross-sectional
and longitudinal studies of healthy smokers suggest that
although inflammation is partially reversible with smok-
ing cessation or even reduction this is not observed in
COPD ex-smokers [48]. Furthermore COPD ex-smokers
have more extensive inflammation than asymptomatic ex-
smokers, including increased sputum neutrophils [49].
Results from this study suggest that cigarette smoke alone
does not promote an "abnormal" inflammatory response
in COPD subjects and may suggest that the development
of COPD in "susceptible" individuals is due to an interac-
tion between environmental and genetic factors.
Much work investigating the mechanism of cigarette
smoke effect on neutrophil infiltration and apoptosis has
suggested that exposure to cigarette smoke initiates NFκB
activation, potentially in macrophages, that leads to infil-
tration of neutrophils to the airways in vivo [50,51] and
the use of acrolein, a toxic aldehyde found in cigarette
smoke, in in vitro experiments can inhibit an number of
important kinases and spontaneous neutrophil apoptosis
[52]. Several similarities in the inflammatory response
(including neutrophil apoptosis and activation of NFκB)
between COPD and healthy smokers in this study may
suggest that the observed inflammation is a consequence
of smoking. However, the majority of COPD subjects
were ex-smokers and therefore support the notion that the
inflammatory response in ex-smokers with COPD is due
the disease process itself [53] and perhaps it is the remod-
elling in COPD that maintains this inflammatory process
[49].
Conclusion
In summary, this study provides evidence for a reduction
in the percentage of neutrophils that have undergone
spontaneous apoptosis in the airways of COPD subjects
using morphological identification of apoptosis, quantifi-
cation of phosphatidylserine exposure and DNA fragmen-
tation. It is likely that the prolonged neutrophil survival
reported in this study in COPD subjects may be due to
altered expression of genes associated with apoptosis that
are controlled by NFκB. The similarity in neutrophil
apoptosis and in some inflammatory markers between
smokers and subjects with COPD needs to be further
investigated with more diverse and larger subject groups
to determine factors associated with disease progression
versus inflammation associated with smoking per se.
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